当前位置: X-MOL 学术Engineering › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment
Engineering ( IF 10.1 ) Pub Date : 2020-10-01 , DOI: 10.1016/j.eng.2020.02.006
Jiajia Chen 1 , Chenxia Hu 1 , Lijun Chen 1 , Lingling Tang 2 , Yixin Zhu 2 , Xiaowei Xu 1 , Lu Chen 3 , Hainv Gao 2 , Xiaoqing Lu 1 , Liang Yu 1 , Xiahong Dai 2 , Charlie Xiang 1 , Lanjuan Li 1, 2
Affiliation  

Abstract H7N9 viruses quickly spread between mammalian hosts and carry the risk of human-to-human transmission, as shown by the 2013 outbreak. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was used to treat H7N9-induced ARDS in 2013. The transplant of MSCs into patients with H7N9-induced ARDS was conducted at a single center through an open-label clinical trial. Based on the principles of voluntariness and informed consent, 44 patients with H7N9-induced ARDS were included as a control group, while 17 patients with H7N9-induced ARDS acted as an experimental group with allogeneic menstrual-blood-derived MSCs. It was notable that MSC transplantation significantly lowered the mortality of the experimental group, compared with the control group (17.6% died in the experimental group while 54.5% died in the control group). Furthermore, MSC transplantation did not result in harmful effects in the bodies of four of the patients who were part of the five-year follow-up period. Collectively, these results suggest that MSCs significantly improve the survival rate of H7N9-induced ARDS and provide a theoretical basis for the treatment of H7N9-induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (e.g., ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.

中文翻译:

间充质干细胞治疗流行性甲型流感(H7N9)感染引起的急性呼吸窘迫综合征的临床研究,为 COVID-19 治疗提供线索

摘要 H7N9 病毒在哺乳动物宿主之间迅速传播,并具有人际传播的风险,如 2013 年的爆发所示。急性呼吸窘迫综合征(ARDS)、肺衰竭和暴发性肺炎是 H7N9 患者的主要肺部疾病。间充质干细胞(MSCs)移植是治疗病毒性肺炎的一种有前景的选择,2013 年用于治疗 H7N9 引起的 ARDS。开放标签临床试验。根据自愿和知情同意的原则,44例H7N9所致ARDS患者作为对照组,17例H7N9所致ARDS患者作为异基因经血来源间充质干细胞实验组。值得注意的是,与对照组相比,MSC移植显着降低了实验组的死亡率(实验组死亡17.6%,对照组死亡54.5%)。此外,MSC 移植并未对 5 年随访期的 4 名患者的身体造成有害影响。总的来说,这些结果表明MSCs显着提高了H7N9引起的ARDS的存活率,并在临床前研究和临床研究中为H7N9引起的ARDS的治疗提供了理论依据。由于 H7N9 和 2019 年冠状病毒病 (COVID-19) 具有相似的并发症(例如 ARDS 和肺衰竭)和相应的多器官功能障碍,因此基于 MSC 的疗法可能是治疗 COVID-19 的一种可能替代方法。实验组死亡 6%,对照组死亡 54.5%)。此外,MSC 移植并未对 5 年随访期的 4 名患者的身体造成有害影响。总的来说,这些结果表明MSCs显着提高了H7N9引起的ARDS的存活率,并为临床前研究和临床研究中H7N9引起的ARDS的治疗提供了理论依据。由于 H7N9 和 2019 年冠状病毒病 (COVID-19) 具有相似的并发症(例如 ARDS 和肺衰竭)和相应的多器官功能障碍,因此基于 MSC 的疗法可能是治疗 COVID-19 的一种可能替代方法。实验组死亡 6%,对照组死亡 54.5%)。此外,MSC 移植并未对 5 年随访期的 4 名患者的身体造成有害影响。总的来说,这些结果表明MSCs显着提高了H7N9引起的ARDS的存活率,并在临床前研究和临床研究中为H7N9引起的ARDS的治疗提供了理论依据。由于 H7N9 和 2019 年冠状病毒病 (COVID-19) 具有相似的并发症(例如 ARDS 和肺衰竭)和相应的多器官功能障碍,因此基于 MSC 的疗法可能是治疗 COVID-19 的一种可能替代方法。在为期五年的随访期间,MSC 移植并未对四名患者的身体产生有害影响。总的来说,这些结果表明MSCs显着提高了H7N9引起的ARDS的存活率,并在临床前研究和临床研究中为H7N9引起的ARDS的治疗提供了理论依据。由于 H7N9 和 2019 年冠状病毒病 (COVID-19) 具有相似的并发症(例如 ARDS 和肺衰竭)和相应的多器官功能障碍,因此基于 MSC 的疗法可能是治疗 COVID-19 的一种可能替代方法。在为期五年的随访期间,MSC 移植并未对四名患者的身体产生有害影响。总的来说,这些结果表明MSCs显着提高了H7N9引起的ARDS的存活率,并为临床前研究和临床研究中H7N9引起的ARDS的治疗提供了理论依据。由于 H7N9 和 2019 年冠状病毒病 (COVID-19) 具有相似的并发症(例如 ARDS 和肺衰竭)和相应的多器官功能障碍,因此基于 MSC 的疗法可能是治疗 COVID-19 的一种可能替代方法。
更新日期:2020-10-01
down
wechat
bug